157 related articles for article (PubMed ID: 35400000)
41. The RANKL-RANK Axis: A Bone to Thymus Round Trip.
Sobacchi C; Menale C; Villa A
Front Immunol; 2019; 10():629. PubMed ID: 30984193
[TBL] [Abstract][Full Text] [Related]
42. An unusual case of polyostotic fibrous dysplasia-A case report.
Jagtap KS; Patel NR; Hiray P; Wadhwa A
Indian J Dent Res; 2020; 31(4):640-643. PubMed ID: 33107470
[TBL] [Abstract][Full Text] [Related]
43. Expression of receptor activator of nuclear factor kappa-B ligand (RANKL) in neoplasms of dogs and cats.
Barger AM; Fan TM; de Lorimier LP; Sprandel IT; O'Dell-Anderson K
J Vet Intern Med; 2007; 21(1):133-40. PubMed ID: 17338161
[TBL] [Abstract][Full Text] [Related]
44. Monostotic craniofacial fibrous dysplasia: report of two cases with interesting histology.
Singh V; Gupta K; Salunke P
Autops Case Rep; 2019; 9(2):e2018092. PubMed ID: 31321219
[TBL] [Abstract][Full Text] [Related]
45. Monostotic fibrous dysplasia of the thoracic spine: A case report.
Ren K; Lan T; Yu Z; Chen Y; Tian CQ; Gu HS; Yang XJ
J Back Musculoskelet Rehabil; 2016 Apr; 29(2):387-391. PubMed ID: 26577280
[TBL] [Abstract][Full Text] [Related]
46. Administration of anti-receptor activator of nuclear factor-kappa B ligand (RANKL) antibody for the treatment of osteoporosis was associated with amelioration of hepatitis in a female patient with growth hormone deficiency: a case report.
Takeno A; Yamamoto M; Notsu M; Sugimoto T
BMC Endocr Disord; 2016 Nov; 16(1):66. PubMed ID: 27881164
[TBL] [Abstract][Full Text] [Related]
47. The role of sclerostin/dickkopf-1 and receptor activator of nuclear factor kB ligand/osteoprotegerin signalling pathways in the development of osteoporosis in patients with haemophilia A and B: A cross-sectional study.
Anagnostis P; Vakalopoulou S; Christoulas D; Paschou SA; Papatheodorou A; Garipidou V; Kokkoris P; Terpos E
Haemophilia; 2018 Mar; 24(2):316-322. PubMed ID: 29194852
[TBL] [Abstract][Full Text] [Related]
48. Malignant B-lymphoid cells with bone lesions express receptor activator of nuclear factor-kappaB ligand and vascular endothelial growth factor to enhance osteoclastogenesis.
Shibata H; Abe M; Hiura K; Wilde J; Moriyama K; Sano T; Kitazoe K; Hashimoto T; Ozaki S; Wakatsuki S; Kido S; Inoue D; Matsumoto T
Clin Cancer Res; 2005 Sep; 11(17):6109-15. PubMed ID: 16144909
[TBL] [Abstract][Full Text] [Related]
49. Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.
Yamagishi T; Kawashima H; Ogose A; Ariizumi T; Sasaki T; Hatano H; Hotta T; Endo N
PLoS One; 2016; 11(5):e0154680. PubMed ID: 27163152
[TBL] [Abstract][Full Text] [Related]
50. Fibrous dysplasia-recent concepts.
Anitha N; Sankari SL; Malathi L; Karthick R
J Pharm Bioallied Sci; 2015 Apr; 7(Suppl 1):S171-2. PubMed ID: 26015701
[TBL] [Abstract][Full Text] [Related]
51. Expression of RANKL by peripheral neutrophils and its association with bone mineral density in COPD.
Hu X; Sun Y; Xu W; Lin T; Zeng H
Respirology; 2017 Jan; 22(1):126-132. PubMed ID: 27552066
[TBL] [Abstract][Full Text] [Related]
52. Surgical Treatment Modalities in Pediatric Monostotic Fibrous Dysplasia of Proximal Femur - A Case Series.
Tathe PV; Banik S; Mandal S
J Orthop Case Rep; 2022 Apr; 12(4):13-18. PubMed ID: 36380989
[TBL] [Abstract][Full Text] [Related]
53. The RANKL/RANK/OPG signal trail: significance of genetic polymorphisms in the etiology of postmenopausal osteoporosis.
Wolski H; Drews K; Bogacz A; Kamiński A; Barlik M; Bartkowiak-Wieczorek J; Klejewski A; Ożarowski M; Majchrzycki M; Seremak-Mrozikiewicz A
Ginekol Pol; 2016; 87(5):347-52. PubMed ID: 27304650
[TBL] [Abstract][Full Text] [Related]
54. Heamatococcus pluvialis ameliorates bone loss in experimentally-induced osteoporosis in rats via the regulation of OPG/RANKL pathway.
El-Baz FK; Saleh DO; Abdel Jaleel GA; Hussein RA; Hassan A
Biomed Pharmacother; 2019 Aug; 116():109017. PubMed ID: 31158803
[TBL] [Abstract][Full Text] [Related]
55. Increased RANKL/OPG mRNA ratio in iliac bone biopsies from women with hip fractures.
Abdallah BM; Stilgren LS; Nissen N; Kassem M; Jørgensen HR; Abrahamsen B
Calcif Tissue Int; 2005 Feb; 76(2):90-7. PubMed ID: 15570403
[TBL] [Abstract][Full Text] [Related]
56. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
Liu W; Zhang X
Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
[TBL] [Abstract][Full Text] [Related]
57. Bisphosphonates for the treatment of fibrous dysplasia of bone.
Chapurlat R; Legrand MA
Bone; 2021 Feb; 143():115784. PubMed ID: 33276154
[TBL] [Abstract][Full Text] [Related]
58. Cyperus Rotundus L. extract suppresses RANKL-induced osteoclastogenesis through NFATc1/c-fos downregulation and prevent bone loss in OVX-induced osteoporosis rat.
Kum CJ; Kim EY; Kim JH; Lee B; Min JH; Heo J; Kim JH; Yeom M; Sohn Y; Jung HS
J Ethnopharmacol; 2017 Jun; 205():186-194. PubMed ID: 28315458
[TBL] [Abstract][Full Text] [Related]
59. A Closer Look at Fibrous Dysplasia Femur Fracture Five-year Follow-up: A Unique Case.
Sauhta R; Makkar D
J Orthop Case Rep; 2024 Feb; 14(2):155-159. PubMed ID: 38420235
[TBL] [Abstract][Full Text] [Related]
60. Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy.
Gifre L; Ruiz-Gaspà S; Carrasco JL; Portell E; Vidal J; Muxi A; Monegal A; Guañabens N; Peris P
Osteoporos Int; 2017 Sep; 28(9):2707-2715. PubMed ID: 28580511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
